EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients-Reference-Cited by-同舟云学术

EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients

Published:2017-12 Issue:6 Volume:140 Page:1703-1705
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Thijs Judith L.^ORCID,Drylewicz Julia^ORCID,Fiechter Renée,Strickland Ian,Sleeman Matthew A.,Herath Athula^ORCID,May Richard D.,Bruijnzeel-Koomen Catharina A.F.M.,Knol Edward F.,Giovannone Barbara,de Bruin-Weller Marjolein S.,Nierkens Stefan,Hijnen Dirk Jan^ORCID

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference9 articles.

1. Biomarkers for atopic dermatitis: a systematic review and meta-analysis;Thijs;Curr Opin Allergy Clin Immunol,2015

2. Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity;Landheer;J Am Acad Dermatol,2014

3. A panel of biomarkers for disease severity in atopic dermatitis;Thijs;Clin Exp Allergy,2015

4. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine;Imai;Int Immunol,1999

5. Interleukin-2 and the interleukin-2 receptor complex;Gaulton;Chem Immunol,1994

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers in atopic dermatitis;Journal of Allergy and Clinical Immunology;2023-05

2. EASI p-EASI: Predicting Disease Severity in Patients with Atopic Dermatitis Treated with Tralokinumab;Journal of Investigative Dermatology;2022-12

3. Multispectral raster-scanning optoacoustic mesoscopy differentiate lesional from non-lesional atopic dermatitis skin using structural and functional imaging markers;Photoacoustics;2022-12

4. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry;Pediatric Allergy and Immunology;2022-12

5. Atopic Dermatitis: Striving for Reliable Biomarkers;Journal of Clinical Medicine;2022-08-09